This is an H2 - use an H3 tag if you want it to show up in the indexwant it to show up in the index

‍

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the This is an inline link

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

This is an H3 use an H3 tag if you want it to show up in the indexwant it to show up in the indexuse an H3 tag if you want it to show up in the indexwant it to show up in the indexuse an H3 tag if you want it to show up in the indexwant it to show up in the index

1. Lack of visibility and connection to relevant investors: Researchers struggle to connect and acquire funding from private investors
2. Legal complexity of IP deals: Deals such as license agreements surrounding pre-patent and patent IP are complex and often need legal support.
3. Difficulty of determining the value of early-stage biopharma assets: Both funders and researchers have trouble assessing the value of early-stage research.

NFTs have created an unprecedented revolution in the creative space, rethinking copyright, royalties and IP. We believe it will also be instrumental in solving the above-stated problems. In this article, we are g

This is an H4

oing to focus on the first technical implementation of a biopharma IPNFT. It builds on many concepts other influential thinkers in the Web3 space have conjured in the past. For example, if you are interested in how general IP can be combined with NFTs have a look at Trent McConaghy 3 part series on building IP NFTs with ERC721. This is regular bold textin the past. For example, if you are interested in how general IP can be combined with NFTs have a look at Trent McConaghy 3 part series on building IP NFTs with ERC721.

Thisioing to focus on the first technical implementation of a biopharma IPNFT. It builds on many concepts other influential thinkers in the Web3 space have conjured in the past. For exoing to focus on the first technical implementation of a biopharma IPNFT. It builds on many concepts other influential thinkers in the Web3 space have conjured in the past. For exoing to focus on the first technical implementation of a biopharma IPNFT. It builds on many concepts other influential thinkers in the Web3 space have conjured in the past. For ex

“When examining the transactional market for biopharma IP, one aspect becomes immediately obvious: IP is not sold in a simple purchase agreement like houses, cars or other physical objects. Transactions involving biopharma IP always differentiate between the specific rights and relating terms of the purchase.”

• Difficulty of determining the value of early-stage biopharma assets: Both funders and researchers have trouble assessing the value of early-stage research.
• Difficulty of determining the value of early-stage biopharma assets: Both funders and researchers have trouble assessing the value of early-stage research.
• Difficulty of determining the value of early-stage biopharma assets: Both funders and researchers have trouble assessing the value of early-stage research.
  

This is just a paragraph

This is just another paragraph conjured in the past. For exoing to focus on the first technical implementation of a biopharma IPNFT. It builds on many concepts other influential thinkers in the Web3 space have conjured in the past. For exoing to focus on the first technical implementation of a biopharma IPNFT. It build